IP Library Granted Patent US 11,413,329
Granted Patent B2
US 11,413,329 · App. 14/436,601 · Granted Aug 16, 2022

Cancer cell trap

Inventor: Liping Tang (Arlington, TX)
Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
A61K38/1816A61K9/5036A61K38/195A61K38/28A61K38/30A61K38/385A61K45/06A61K47/10A61K47/34A61L31/041A61L31/129A61L31/145A61L31/16G01N33/5091A61K9/06A61K38/18A61K38/1833A61K38/1866A61K38/2053A61K47/32A61L2300/414A61L2300/416A61L2300/426G01N2800/7028
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,413,329
App. No.
14/436,601
Granted
Aug 16, 2022
Kind
B2
Abstract

The present invention is directed to cancer cell traps and methods of using cancer cell traps to treat and detect metastatic cancer in subjects. The cancer cell traps are administered to subjects and induce the migration and accumulation of metastatic cancer cells in the cancer cell traps.

Claims (15)

1. A method for treating cancer metastasis comprising administering to a subject in need thereof an effective amount of a cancer cell trap, wherein the cancer cell trap comprises

i. microparticles;

ii. nanoparticles;

iii. a scaffold structure; or

iv. a hydrogel,

wherein circulating cancer cells are recruited to the cancer cell trap;

wherein the circulating cancer cells are selected from the group consisting of leukemia cells, melanoma cells, prostate cancer cells, and lung cancer cells,

wherein the cancer cell trap comprises erythropoietin (EPO) that is released from the cancer cell trap, wherein the EPO enables recruitment and accumulation of circulating cancer cells in the cancer cell trap, and

wherein the cancer cell trap further comprises a chemotherapeutic agent and/or the method further comprises subjecting the cancer cell trap to radiation.

2. The method of claim 1 , wherein the scaffold structure comprises a degradable polymer and polypeptides.

3. The method of claim 1 , wherein the cancer cell trap comprises PLGA, albumin, collagen, gelatin, immunoglobulins, extracellular matrix proteins, fibronectin and combinations thereof.

4. The method of claim 1 , wherein the cancer cell trap is implanted into the subject.

5. The method of claim 1 , wherein the cancer cell trap is injected into the subject.

6. The method of claim 1 , wherein the subject is a human.

7. The method of claim 1 , wherein the chemotherapeutic agent is a member selected from the group consisting of cytotoxic agents, DNA-alkylating agents, anti-tumor antibiotic agents, anti-metabolic agents, tubulin stabilizing agents, tubulin destabilizing agents, hormone antagonist agents, topoisomerase inhibitors, protein kinase inhibitors, HMG-CoA inhibitors, CDK inhibitors, cyclin inhibitors, caspase inhibitors, metalloproteinase inhibitors, antisense nucleic acids, triple-helix DNAs, nucleic acids aptamers, and molecularly-modified viral, bacterial, exotoxic agents, and combinations thereof.

Assignments (1)
CONFIRMATORY LICENSE Recorded Jan 17, 2024
From: UNIVERSITY OF TEXAS ARLINGTON
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 066338/0931 →
Continuity (2)
Provisional Application 61716526 · Oct 20, 2012
Related Publication 20150283073A1 · Oct 8, 2015